BioMarin Pharmaceutical Inc.

Unlock to Claim this listing
Add / Modify Company

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria.

Click to rate this company
[Total: 0 Average: 0]

3.9

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

BioMarin Pharmaceutical takes decisive strides toward environmental stewardship by integrating sustainable strategies across its operations, encompassing energy-efficient manufacturing, responsible supply chain management, waste reduction initiatives, and sustainable packaging solutions, all strategically aimed at reducing its ecological footprint and promoting a culture of environmental responsibility that echoes its core mission of contributing to a healthier planet.A vanguard of positive social impact, BioMarin Pharmaceutical elevates its role in transforming lives through rare disease therapies, channeling its innovative product portfolio toward addressing unmet medical needs, while actively engaging in patient support initiatives, community collaborations, and healthcare education programs, thus fostering a holistic and meaningful approach to societal well-being. BioMarin Pharmaceutical’s unwavering commitment to research excellence and innovation underpins its ESG sustainability strategy, as it persistently advances pioneering therapies that address rare diseases, improve patient outcomes, and drive medical science forward, all while maintaining a steadfast adherence to the highest ethical standards, research integrity, and a patient-centric ethos that underscores its pivotal role in transforming healthcare landscapes.The bedrock of BioMarin Pharmaceutical’s ESG framework rests upon a foundation of exemplary governance practices, underscored by a culture of transparency, integrity, and accountability that permeates its decision-making processes, facilitated by a diverse and experienced board of directors, rigorous compliance protocols, and ethical conduct that positions the company as a model of responsible corporate leadership.BioMarin Pharmaceutical’s financial sustainability harmoniously intertwines with its ESG imperatives, as its financial growth is inextricably linked to its ability to develop and provide groundbreaking rare disease treatments that resonate with patients, healthcare professionals, and investors who recognize the inherent value of responsible innovation and sustainable business practices. BioMarin Pharmaceutical’s stakeholder engagement philosophy thrives on inclusivity and collaboration, extending to patients, healthcare professionals, employees, communities, and investors, fostering an environment of open dialogue, attentive listening, and transparent communication that shapes its strategies, aligns with societal aspirations, and underscores its unwavering dedication to advancing healthcare and societal well-being.BioMarin Pharmaceutical Inc., an innovative and forward-looking biopharmaceutical company renowned for its steadfast commitment to rare disease therapies, epitomizes an all-encompassing dedication to ESG (Environment, Social, Governance) sustainability that intricately weaves through the fabric of its operations, showcasing its unwavering ethical compass, positive societal impact, and enduring value creation, while remaining resolutely aligned with the diverse needs of patients, healthcare partners, and global stakeholders, thereby exemplifying a profound and responsible approach to pioneering advancements in rare disease treatment through sustainable business practices.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$2,000,000,000.00

Website Traffic

Employee Rating

4.2

Customer Rating

3.9

Company Size

1000-5000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.